CA2858821A1 - Simethicone formulation - Google Patents

Simethicone formulation Download PDF

Info

Publication number
CA2858821A1
CA2858821A1 CA 2858821 CA2858821A CA2858821A1 CA 2858821 A1 CA2858821 A1 CA 2858821A1 CA 2858821 CA2858821 CA 2858821 CA 2858821 A CA2858821 A CA 2858821A CA 2858821 A1 CA2858821 A1 CA 2858821A1
Authority
CA
Canada
Prior art keywords
simethicone
calcium phosphate
mannitol
weight
phosphate powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2858821
Other languages
English (en)
French (fr)
Inventor
Jose Luis Velada
Hiteshkumar Anilkant Doshi
Anjali Rajesh TENDULKAR
Vicky SHINDE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Disphar International BV
Original Assignee
Disphar International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Disphar International BV filed Critical Disphar International BV
Publication of CA2858821A1 publication Critical patent/CA2858821A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036—Silicones; Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA 2858821 2011-12-14 2012-12-11 Simethicone formulation Abandoned CA2858821A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11193452.7 2011-12-14
EP11193452 2011-12-14
PCT/NL2012/050879 WO2013095111A1 (en) 2011-12-14 2012-12-11 Simethicone formulation

Publications (1)

Publication Number Publication Date
CA2858821A1 true CA2858821A1 (en) 2013-06-27

Family

ID=47628413

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2858821 Abandoned CA2858821A1 (en) 2011-12-14 2012-12-11 Simethicone formulation

Country Status (8)

Country Link
US (1) US20150119422A1 (enExample)
EP (1) EP2790676B1 (enExample)
AU (1) AU2012327176B2 (enExample)
BR (1) BR112014014278A2 (enExample)
CA (1) CA2858821A1 (enExample)
IN (1) IN2014MN01382A (enExample)
RU (1) RU2602745C2 (enExample)
WO (1) WO2013095111A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41620A (fr) 2015-05-14 2018-01-09 Abdi Ibrahim Ilac Sanayi Ve Ticaret A S Composition pharmaceutique comprenant de la siméthicone et de l'otilonium
EP3294269A1 (en) * 2015-06-12 2018-03-21 Santa Farma Ilaç Sanayi A.S. Oral pharmaceutical composition comprising otilonium bromide and simethicone with certain bulk density and improved dissolution characteristics
MX385008B (es) * 2016-12-14 2025-03-14 Rhein Siegfried Sa De Cv Composicion mejorada de lansoprazol y simeticona y procesos para prepararla.
AU2019225236B2 (en) 2018-02-26 2025-01-30 R.P. Scherer Technologies, Llc Pharmaceutical dosage form for an emulsion of simethicone and loperamide
CN116159032A (zh) * 2023-03-31 2023-05-26 成都恒瑞制药有限公司 盐酸西替利嗪片及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4396604A (en) * 1982-05-17 1983-08-02 Norcliff Thayer, Inc. Simethicone antacid lozenge
US6103260A (en) 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US7101573B2 (en) 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
WO2007057924A1 (en) 2005-11-21 2007-05-24 Panacea Biotec Ltd Laxative composition on the basis of triphala
WO2008056200A1 (en) * 2006-11-10 2008-05-15 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of simethicone

Also Published As

Publication number Publication date
EP2790676B1 (en) 2018-01-10
US20150119422A1 (en) 2015-04-30
RU2602745C2 (ru) 2016-11-20
AU2012327176A1 (en) 2013-07-04
EP2790676A1 (en) 2014-10-22
BR112014014278A2 (pt) 2017-06-13
AU2012327176B2 (en) 2015-08-13
IN2014MN01382A (enExample) 2015-04-17
RU2014128604A (ru) 2016-02-10
WO2013095111A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
KR101740835B1 (ko) 작용화 탄산칼슘을 포함하는 속붕해성 고형 제형 제제 및 이의 제조 방법
CA2956538C (en) Directly compressible composition comprising microcrystalline cellulose
LT4896B (lt) Staigiai ištirpstanti peroralinė dozuota vaisto forma
TWI466689B (zh) Antacid tablets with a laxative
JP5610865B2 (ja) 固形製剤
KR102152873B1 (ko) 결장 배출의 용도를 위한 제형 및 제형의 제조 방법
EP2790676B1 (en) Simethicone formulation
JP5318400B2 (ja) レボフロキサシン含有錠剤
RS58214B1 (sr) Farmaceutski sastav koji sadrži kandesartan cileksetil i amlodipin
EA036288B1 (ru) Фармацевтические лекарственные формы
WO2014173515A1 (en) Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
Khemariya et al. Preparation and in-vitro evaluation of sustained-release matrix tablets of Diltiazem
KR20040091135A (ko) 염산 필지카이니드 함유 정제(건식)
Eziuzo et al. Formulation and Evaluation of Floating Matrix Tablets of Ciprofloxacin Using Sida acuta Gum. Against Some Pathogenic Bacteria
KR20240093577A (ko) 약학적 조성물
WO2015106963A1 (en) Pharmaceutical composition comprising aripiprazole or salt thereof
KR100843021B1 (ko) 안정성이 개선된 디에틸프로피온 하이드로클로라이드를포함하는 경구투여용 고형 제제
Shah Taste masking, formulation and evaluation of orally disintegrating tablet of anti-histaminic drug
Parasgar et al. PREPARATION AND EVALUATION OF MATRIX TABLET OF A THIRD GENERATION CEPHALOSPORIN DRUG.
Mishra et al. Formulation and evaluation of fast dissolving tablets of metformin
Mehrban et al. Formulation Development and Evaluation of Sodium Bicarbonate Tablets by Direct Compression Method
Thorat et al. FORMULATION AND EVALUATION OF FAST DISINTEGRATING TABLETS OF ONDANSETRON WITH NATURAL AND SYNTHETIC SUPER DISINTEGRATING AGENTS
Sarada et al. Formulation and evaluation of oral disintegrating tablets of pantoprazole
Jha et al. Formulation and evaluation of glipizide-loaded fast-dissolving tablets using husk of Plantago ovata as a superdisintegrant
CN103446072A (zh) 帕洛诺司琼的固体药物组合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170823

FZDE Discontinued

Effective date: 20200203